<DOC>
	<DOCNO>NCT01029262</DOCNO>
	<brief_summary>The purpose study investigate whether lenalidomide would reduce number red blood cell transfusion ( RBC ) need anemic ( RBC transfusion-dependent ) participant low intermediate-1 risk MDS without deletion 5q chromosome abnormality . The study also investigate safety lenalidomide use participant . Two-thirds participant receive oral lenalidomide one-third participant receive oral placebo .</brief_summary>
	<brief_title>A Study Lenalidomide Versus Placebo Subjects With Transfusion Dependent Anemia Lower Risk Myelodysplastic Syndrome ( MDS ) Without Del 5q</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>18 year old Diagnosis low intermediate1 risk Myelodysplastic ( MDS ) chromosome karyotype except del 5q [ 31 ] Anemia require red blood cell transfusion Resistant erythropoiesis stimulate agent ( ESAs ) blood erythropoietin level &gt; 500 mU/mL Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤ 2 Must agree follow pregnancy precaution require protocol . Must agree receive counsel relate teratogenic risk lenalidomide Must agree donate blood semen Must willing consent two bone marrow aspirate procedure complete study Subjects previously receive immunomodulating immunosuppressive agent , epigenetic deoxyribonucleic acid ( DNA ) modulation agent Allergic reaction thalidomide Renal insufficiency creatinine clearance ( CrC1 ) &lt; 40 mL/min CockcroftGault method ) Prior history cancer , MDS , unless subject free disease ≥ 5 year . ( Basal cell carcinoma skin , carcinoma situ cervix , stage Tumor ( T ) 1a T1b prostate cancer allow ) Absolute neutrophil count ( ANC ) &lt; 500/uL Platelets &lt; 50,000/uL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3X upper limit normal Uncontrolled hyperthyroidism hypothyroidism Significant neuropathy Prior stem cell transplantation Anemia due reason MDS History deep venous thrombosis ( DVT ) pulmonary embolus ( PE ) within past 3 year Significant active cardiac disease within past 6 month Known Human Immunodeficiency Virus ( HIV ) infection ; know Hepatitis C infection active Hepatitis B infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>MDS</keyword>
	<keyword>transfusion dependent anemia</keyword>
	<keyword>Erythropoiesis stimulating agent</keyword>
	<keyword>non-del 5q</keyword>
</DOC>